Hanan Polansky, The Center for the Biology of Chronic Disease, Rochester, NY 14620
Edan Itzkovitz, The Center for the Biology of Chronic Disease, Rochester, NY 14620

Abstract

Introduction: This paper reports the results of a post marketing clinical study that centered on the relationship between treatment with the dietary supplement Gene-Eden-VIR and the severity, duration, and frequency of symptoms reported by individuals infected with the following viruses: Human Papillomavirus (HPV), Herpes Simplex Virus (HSV), Epstein Barr Virus (EBV), Human Cytomegalovirus (HCMV), and Hepatitis C Virus (HCV). The symptoms included abnormal Pap smear, low and high grade cervical dysplasia, warts, blisters, cold sores, hives, skin tabs, panic attacks, depression, kidney problems, sleeping problems, liver problems, fever, fatigue, sore throat, swollen lymph nodes, diarrhea, and weight loss.

Treatment: Every capsule of Gene-Eden-VIR includes 100 mg of quercetin, 150 mg of a green tea extract, 50 mg of a cinnamon extract, 25 mg of a licorice extract, and 100 mcg of selenium. Treatment included 1, 2, 3, or 4 capsules per day, for 2 to 54 weeks.

Population: 60 infected individuals, ages 20 to 66.

Results: The participants reported no side effects. Seventy three percent of the individuals treated with Gene-Eden-VIR reported a decrease in their symptoms. Specifically, they report a decrease in the severity of their symptoms (p<0.001), the duration of their symptoms (p<0.001), the frequency of their symptoms (p<0.001). During treatment with Gene-Eden-VIR, the participants also reported an increase in their physical strength (p<0.001), their energy levels (p<0.001), their concentration (p<0.001), and their general health (p<0.001). The participants also reported a duration effect (p<0.001), that is, those treated with Gene-Eden-VIR for a longer time report a larger decrease in their symptoms. The research showed no interviewer bias, no selection bias, and a surprising response shift. The research also showed that Gene-Eden-VIR has therapeutic consistency under varying manufacturing conditions.

Conclusions: The currently available treatments for individuals infected with the HPV, EBV, HSV, HCMV, and HCV, both natural and FDA approved, have many limitations. This post marketing clinical study showed that infected individuals treated with the natural product Gene-Eden-VIR reported a safe decrease in their symptoms. Therefore, healthcare providers should recommend Gene-Eden-VIR to infected individuals as a possible treatment for their symptoms.

Note: If you would like to read the full paper, please send an email to the Center for the Biology of Chronic Disease (CBCD), and the Center will email you a copy of the paper. The Center's email address is info(at)CBCD.net. Please replace the (at) with the symbol @.

Click here to see the website of Gene-Eden-VIR that includes information for the general public.